Monte Rosa Therapeutics, Inc. (GLUE) KPIs and segments
GLUENasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 7/3041% above fair value
$9.07−0.09 (-0.98%)
Close on Nov 17, 2026Market cap $773.79MP/E –Yield –
KPIs & segments
Operating metrics and segments that drive Monte Rosa Therapeutics's business
Coming soon
This tab will track the numbers specific to Monte Rosa Therapeutics's business model — such as store count, revenue by banner, revenue per store and new openings — taken from filings and earnings releases.
See a number that looks wrong?